Capstone Investment Advisors
APGE

Capstone Investment Advisors’s Apogee Therapeutics APGE Stock Holding History

Capstone Investment Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9M Buy
+120,000
New +$10.8M 0.03% 244
2024
Q2 		– Sell
-41,001
Closed -$2.72M – 2063
2024
Q1 		$2.72M Buy
+41,001
New +$1.79M 0.01% 653

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Capstone Investment Advisors's APGE Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 120,000 shares worth $15.9M. The stake represents 0.03% of the portfolio and ranks #244 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in APGE as recently as Q1 2024.

Capstone Investment Advisors first reported a position in APGE in Q1 2024 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Capstone Investment Advisors held 120,000 shares of Apogee Therapeutics worth $15.9M as of Q2 2026.
  • Apogee Therapeutics was a new Capstone Investment Advisors position in Q2 2026.
  • Apogee Therapeutics made up 0.03% of Capstone Investment Advisors's portfolio in Q2 2026, its #244 holding.
  • Capstone Investment Advisors first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.